Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide and dexamethasone together with bortezomib may kill more cancer cells.

PURPOSE: This phase II trial is studying giving cyclophosphamide and dexamethasone together with bortezomib to see how well it works in treating patients with newly diagnosed multiple myeloma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

NCT02082405

Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma

WITHDRAWN PHASE2

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

NCT00458705

Multiple Myeloma and Plasma Cell Neoplasm

COMPLETED PHASE2

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01212952

Refractory Multiple Myeloma

COMPLETED PHASE1/PHASE2

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00742404

Multiple Myeloma and Plasma Cell Neoplasm

UNKNOWN PHASE2

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

NCT01668719

DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

\* To evaluate the response rate (complete response \[CR\], near CR \[nCR\], and very good partial response) in patients with newly diagnosed multiple myeloma treated with bortezomib in combination with cyclophosphamide and dexamethasone .

Secondary

* Determine the overall response rate (partial response, PR, or better) in these patients after 4, 8, and 12 courses of this regimen.
* Determine the duration of progression-free and overall survival of patients treated with this regimen.
* To evaluate the toxicity of this regimen in these patients.
* To evaluate the ability to successfully collect peripheral blood stem cells from these patients after 4 months of this regimen.
* To evaluate the CR or nCR rate in these patients after 8 and 12 courses of this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral cyclophosphamide on days 1, 8, 15, and 22; bortezomib IV on days 1, 4, 8 , and 11 OR days 1, 8, 15 and 22; and dexamethasone on days 1-4, 9-12, and 17-20 in courses 1 and 2 and days 1, 18, 15, and 22 in all subsequent courses. Courses repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma and Plasma Cell Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bortezomib

First 33 patients: 1.3 mg/m\^2 IV Days 1, 4, 8 \& 11

Remaining 30 patients: 1.5 mg/m\^2 IV Days 1, 8, 15 \& 22

Intervention Type DRUG

cyclophosphamide

300mg/m\^2 PO days 1, 8, 15 \& 22

Intervention Type DRUG

dexamethasone

First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20

Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PATIENT CHARACTERISTICS:

* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2

\- ECOG PS of 3 will be allowed if secondary to pain in the opinion of the Investigator
* Total bilirubin normal OR direct bilirubin ≤ 2.0 mg/dL
* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)
* AST ≤ 3 times ULN
* Creatinine ≤ 3.5 mg/dL
* Absolute neutrophil count ≥ 1,000/mm³ without transfusion or growth factor
* Platelet count ≥ 100,000/mm³ without transfusion or growth factor
* Willingness and the physical and mental capability to provide written informed consent
* Willingness to return to Mayo Clinic Arizona/Princess Margaret Hospital for follow-up
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

Exclusion Criteria

* Peripheral sensory neuropathy ≥ grade 2 as defined by National Cancer Institute (NCI) Common Terminology for Common Adverse Events (CTCAE) version 3.0
* Known hypersensitivity to compounds containing boron or mannitol
* Active uncontrolled infection
* Severe cardiac comorbidity including but not limited to:

* New York Heart Association class III or IV heart failure
* History of myocardial infarction within the past 6 months
* Uncontrolled angina or electrocardiographic (ECG) evidence of acute ischemia
* Severe uncontrolled ventricular arrhythmias or ECG evidence of active conduction system abnormalities
* Cardiac amyloidosis with hypotension (i.e., systolic blood pressure \< 100 mm Hg)
* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent study compliance or completion of study treatment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior high-dose corticosteroid therapy for 12 days or less is permitted for emergent complications from newly diagnosed multiple myeloma
* More than 14 days since prior investigational agents
* No concurrent steroids or any other anticancer agents or treatments

\- Patients may receive the equivalent of up to 20 mg prednisone per day for concurrent illness or adrenal replacement therapy
* Concurrent palliative radiotherapy for bony pain or fracture is allowed

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No